ResMed (NYSE: RMD) + announced that it acquired respiratory care diagnostics software developer Somnoware.
This move marks the second software buy in the past year for ResMed. The San Diego-based sleep respiratory treatment maker bought Medifox Dan for $1 billion in November 2022. Medifox Dan develops clinical, financial and operational software for out-of-hospital care providers. It offers care documentation, personnel planning, administration and billing, among other things.
ResMed declined to disclose the financial terms of the transaction. The company said the terms remain immaterial to its consolidated financial results.
Somnoware designed its software to streamline the processes of physicians and sleep and pulmonary function testing labs as they diagnose and evaluate sleep and respiratory care test results. Through the platform, positive airway pressure (PAP) therapy can run more efficiently.
It ena…